Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CD79B and MYD88 mutations in diffuse large B-cell lymphoma.

Human pathology - 1 Mar 2014

Kim Yuil, Ju Hyunjeong, Kim Dong Hoon, Yoo Hae Yong, Kim Suk Jin, Kim Won Seog, Ko Young Hyeh

Abstract excerpt

Mutations in 2 upstream components of the nuclear factor κB (NF-κB) pathway, CD79B and MYD88, are important information for new target therapy in malignant lymphoma. We examined the prevalence and clinicopathologic characteristics of CD79B and MYD88 mutation in a cohort of Asian diffuse large B cell lymphoma (DLBCL) patients. CD79B and MYD88 mutations were analyzed by Sanger sequencing in 187 DLBCL tissue...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD79 Antigens

Share to Lymphoma, Large B-Cell, Diffuse

Share to Mutation

Share to Myeloid Differentiation Factor 88

Share to Prognosis

Source

Identifiers

PMID: 24444466
DOI: 10.1016/j.humpath.2013.10.023

Genes

MYD88

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CD79B and MYD88 mutations in diffuse large B-cell lymphoma.PMID 24444466Read ↗

MYD88 <sup>L265P</sup> and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapySemantic proximity Read ↗

Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.Semantic proximity Read ↗

Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical PracticeSemantic proximity Read ↗

High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sitesSemantic proximity Read ↗

MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes.Semantic proximity Read ↗

Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature Review.Semantic proximity Read ↗

Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.Semantic proximity Read ↗

MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications.Semantic proximity Read ↗

Prevalence and prognostic value of MYD88 and CD79B mutations in ocular adnexal large B-cell lymphoma: a reclassification of ocular adnexal large B-cell lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.